GHK-Cu
Small skin studies only; no controlled hair or injection trials.
Three amino acids carrying a copper ion, found naturally in blood at levels that decline with age. In creams and serums it is an ordinary cosmetic ingredient. Injected, it has no human data. A , also called Copper tripeptide-1 and Copper peptide.
What the evidence shows
Side effects and risks
Who should avoid it: Injected forms. People with Wilson's disease, who cannot clear copper, should be cautious.
How it works
- Where it acts
- It carries copper into cells. In lab studies it switches on genes for collagen and tissue repair.
- What it changes
- On skin, more collagen and repair signals in small studies.
- What people notice
- In creams, modest changes in skin texture in small trials. Injected, there is no human data.
How it has been given in studies
Applied to the skin as a cream or serum for 8 to 12 weeks. There is no human dose for injection.
Getting it in the United States
The legal route for GHK-Cu
Sold without a prescription as a cosmetic or food supplement. In most countries no one checks that these products work before sale.
Over-the-counter cosmetic creams and serums
Topical versions have been sold as cosmetics for decades without drug approval. Main risk reported is products with too little peptide to matter in a poorly regulated market.
Source: Abud Bakri Substack, 2023-12
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Unregulated online sellers
Most injectors buy vials online for home use and pay out of pocket, with no follow-up blood tests. Purity and strength are unknown.
Source: Medical Daily, 2026-09
Compounding pharmacy via prescriber
The FDA said in 2026 it would take injectable GHK-Cu off its safety-concern list, but lawyers note that alone does not make compounding eligible. An advisory committee review is due before February 2027.
Source: Goodwin law firm blog, 2026-05
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- Smoother, brighter skin from serums
Reported problems
- Stinging or irritation
- Painful injections, with tiredness afterwards
- Blue stains on fabric
Serum reports are hard to separate from the effect of any good moisturizer.
What experts and influencers say
Recorded views, not a survey or scientific consensus. Cautions may concern misuse or unapproved products. Statements are paraphrased; check each source for context.
Supportive expert view
Wrote that he used a topical copper peptide for about two months and saw healthier skin and thicker eyebrows. Conceded the research is mostly small, old or animal studies.
Source: Abud Bakri Substack, 2023-12
Abud BakriWebsiteRecommendsSays they used it
Money: States he gains nothing from sales; says he knows the owner of the brand he uses
Photo source: hubermanlab.com
Cautionary expert view
Calls the craze unfounded. He found no randomized human trial showing the advertised benefits for any of the unapproved peptides he reviewed, and warns about stacking several at once. He points to animal work in which TB-500 sped up dormant tumor growth and to a theoretical cancer concern with growth-hormone peptides and BPC-157. He treats the GLP-1 drugs as the well-studied exception.
Source: Eric Topol, "The Peptide Craze", Jul 2025, Associated Press, Nov 2025
Eric TopolWebsiteWarns against
See all views 13
Calls the craze unfounded. He found no randomized human trial showing the advertised benefits for any of the unapproved peptides he reviewed, and warns about stacking several at once. He points to animal work in which TB-500 sped up dormant tumor growth and to a theoretical cancer concern with growth-hormone peptides and BPC-157. He treats the GLP-1 drugs as the well-studied exception.
Source: Eric Topol, "The Peptide Craze", Jul 2025, Associated Press, Nov 2025
Eric TopolWebsiteWarns against
Called the science behind topical copper peptide solid. Said injection could plausibly deliver more of the molecule but advised patients to wait for human studies.
Source: Medical Daily, 2026-09
David GoldbergWebsiteMixed view
Photo source: aestheticextendersymposium.com
Wrote that he used a topical copper peptide for about two months and saw healthier skin and thicker eyebrows. Conceded the research is mostly small, old or animal studies.
Source: Abud Bakri Substack, 2023-12
Abud BakriWebsiteRecommendsSays they used it
Money: States he gains nothing from sales; says he knows the owner of the brand he uses
Photo source: hubermanlab.com
Warned that most people injecting it buy from unregulated suppliers with no assurance of quality or strength, and that the vial may not contain a copper peptide at all.
Source: Medical Daily, 2026-09
Marisa GarshickInstagramWarns against
Believes the compound may help longevity and says animal data suggest it is fairly safe. Said he would not inject it himself and doubts federal approval will come because it is hard to patent.
Source: Medical Daily, 2026-09
Warren LadigesWebsiteMixed view
Photo source: halo.dlmp.uw.edu
Told the public not to buy or use peptides sold online. Reported serious cases with hospital stays, notably after retatrutide. Ordered several products presented as GLP-1 drugs off the market in July and August 2026.
Source: ANSM, Jul 2026
Reported that most of his consultations involve people who bought and injected it, then became worried. Said topical forms do more for skin and hair than injections.
Source: Medical Daily, 2026-09
Erik MarksWebsiteMixed view
Money: Offers the compound in his own practice, sourced from a compounding pharmacy
Photo source: vitalitymedicalpnw.com
Told AFP that many of these molecules have never been tested in humans and that self-experiment stories shared online carry no scientific weight.
Source: Sud Radio / AFP, Aug 2026
Armelle RancillacWebsiteWarns against
Photo source: college-de-france.fr
Hosted an episode on grey-market injectable peptides with a journalist and an Imperial College peptide researcher. It asked how unregulated compounds won a following among biohackers and what they may do in the body.
Madeleine FinlayWebsiteMixed view
Photo source: madeleinefinlay.com
Wrote that the 2026 French alert goes beyond the GLP-1 fakes flagged in 2025, and that some products are passed off as food supplements or carry research-only labels that buyers should not trust.
Source: Vidal, Jul 2026
Irene DrogouWebsiteWarns against
Photo source: lequotidiendumedecin.fr
Imposed a trade ban on two peptide websites and has more investigations open. Says selling medicines without a licence is illegal even with a research-only label, and calls buying them life-threatening.
Source: AVROTROS Radar, Mar 2026
IGJ (Health and Youth Care Inspectorate)SourceWarns against
Said the skin claims made for GHK-Cu have almost no scientific basis. The evidence is mostly small observational studies, not randomised trials.
Source: AVROTROS Radar, Mar 2026
Tom DecatesWebsiteWarns against
Photo source: erasmusmc.nl
Told the public not to inject peptides bought online. Said unauthorized products are illegal, unproven and may cause organ damage, clots or tumour growth. A research-use-only label does not make them legal.
Source: Health Canada advisory, 2026-04
Health CanadaSourceWarns against
More contextCase reports, watch and read, emerging uses and chemistry
Case reports
From journals, regulators and studies of users. One case proves little.
Harm reportednews-reported case - 2026
A Seattle-area clinician reported seeing self-injectors with injection site irritation, infection, raised liver enzymes and raised copper levels after heavy use. He could not tell whether the peptide, an impurity or an undisclosed substance was the cause.
Source: Medical Daily, 2026-09
Benefit reportedcase report - 1 person - 2023
A physician-writer self-reported better looking skin and thicker eyebrows after about two months of a topical copper peptide product. Uncontrolled personal observation with no measurements.
Source: Abud Bakri Substack, 2023-12
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
People are injecting copper peptides ahead of the science
Will Stone, NPR health reporter
Radio report on copper peptides moving from skin creams to injections, noting thin human evidence, gray-market sourcing and reported injection-site problems.
Best short reality check on injectable GHK-Cu.
Inside the booming, gray-market world of injectable peptides
Joseph Choi, reporter
Reporter shows how easy it is to order a research-grade vial online, while experts warn about unapproved products, mislabeling and no physician oversight.
Investigative look at the gray market where GHK-Cu is sold.
5 Things to Know About the FDA's Peptide Reversal
Habiba Atta, writer
Explains how the 2026 FDA peptide reversal affects GHK-Cu, expected to return to the compounding-eligible list, while career scientists cite thin human safety data.
Clarifies GHK-Cu's current US regulatory status.
When options run out
Uses people turn to when standard treatment has failed.
Self-injection for longevity or organ repair
- Who
- Self-experimenters chasing systemic anti-aging effects beyond what a cream offers.
- Evidence
- Animal studies show wound healing and organ repair signals, including in lung fibrosis models. No human injection safety data exists.
Source: Medical Daily, 2026-09
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Carries one copper ion.
Questions people ask
Does copper peptide (GHK-Cu) work for skin?
Small studies, many unpublished or linked to manufacturers, suggest modest changes in skin texture. One randomized eight-week trial reported 56% less wrinkle volume than a control serum.
Does GHK-Cu help hair growth?
No controlled human trial was found. The evidence for hair comes from the lab only.
Is injecting GHK-Cu safe?
Injected, it has no human data, and doses quoted online are scaled up from rats. FDA cites the risk of immune reactions from clumping and impurities.
What are the side effects of GHK-Cu?
Occasional skin irritation or stinging from serums. People who inject it report painful injections and tiredness afterwards, and serums can leave blue stains on fabric.
Is GHK-Cu legal?
In creams and serums it is a cosmetic ingredient in the US, EU, UK, Canada and Australia, but the injectable form is not approved, authorized or registered in any of them. FDA advisers are due to review it for compounding by February 2027.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- Pickart & Margolina 2018: review of GHK-Cu studies
- FDA: bulk substances that may present significant safety risks
- FDA Law Blog: which peptides go to the advisory committee (Apr 2026)
Structure: PubChem